On the public citation graph

Relative Risk of Hepatotoxicity Associated With BCR-ABL Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis

0 signed · 20 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.

Claim with ORCID

Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.

See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jamaoncol.2015.5932openalex-extracted

Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival

inferredcites →https://doi.org/10.1002/ajh.20486openalex-extracted

Imatinib mesylate as a cause of acute liver failure

inferredcites →https://doi.org/10.1002/cncr.26679openalex-extracted

Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

inferredcites →https://doi.org/10.1007/s00277-015-2314-2openalex-extracted

Epidemiology of chronic myeloid leukaemia: an update

inferredcites →https://doi.org/10.1016/j.clml.2016.03.003openalex-extracted

Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials

inferredcites →https://doi.org/10.1016/j.ejca.2018.08.016openalex-extracted

Comparative efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukaemia: A systematic review and network meta-analysis

inferredcites →https://doi.org/10.1016/s0140-6736(13)62120-0openalex-extracted

Chronic myeloid leukaemia

inferredcites →https://doi.org/10.1038/leu.2013.320openalex-extracted

Fatal progressive cerebral ischemia in CML under third-line treatment with ponatinib

inferredcites →https://doi.org/10.1080/10428190802136384openalex-extracted

Dasatinib-induced acute hepatitis

inferredcites →https://doi.org/10.1080/14740338.2017.1261824openalex-extracted

Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis

inferredcites →https://doi.org/10.1182/bloodadvances.2019001329openalex-extracted

First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis

inferredcites →https://doi.org/10.1186/2162-3619-2-5openalex-extracted

The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis

inferredcites →https://doi.org/10.12809/hkmj187420openalex-extracted

Rechallenge of ponatinib in chronic myeloid leukaemia after hepatotoxicity

inferredcites →https://doi.org/10.1287/lytx.2021.01.17openalex-extracted

ReCAP: Marcy Jance

inferredcites →https://doi.org/10.14309/crj.0000000000000003openalex-extracted

A Case of Severe, Nilotinib-Induced Liver Injury

inferredcites →https://doi.org/10.18632/oncotarget.4400openalex-extracted

A comprehensive study of the association between drug hepatotoxicity and daily dose, liver metabolism, and lipophilicity using 975 oral medications

inferredcites →https://doi.org/10.2147/cmar.s177566openalex-extracted

First-line treatment strategies for newly diagnosed chronic myeloid leukemia: a network meta-analysis

inferredcites →https://doi.org/10.26532/jh.v35i2openalex-extracted

inferredcites →https://doi.org/10.3324/haematol.2012.063172openalex-extracted

Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis

inferredcites →https://doi.org/10.7759/cureus.4411openalex-extracted

Novel Score-based Decision Approach in Chronic Myeloid Leukemia Patients After Acute Toxic Imatinib-induced Liver Injury

Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.